Acadia Pharma (ACAD) Tops Q1 EPS by 13c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $25.97 +3.06%
Revenue Growth %: +11.8%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
CRMT, More
Revenue Growth %: +11.8%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of $0.11, $0.13 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $244.32 million versus the consensus estimate of $239.55 million.
GUIDANCE:
Acadia Pharma sees FY2025 revenue of $1.03-1.09 billion, versus the consensus of $1.06 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Freedom Broker Starts Unity Bancorp (UNTY) at Hold
- Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
